{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T07:08:39Z","timestamp":1784099319104,"version":"3.55.0"},"reference-count":32,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100003185","name":"National Psoriasis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100003185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000296","name":"British Skin Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000296","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100013126","name":"Psoriasis Association","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013126","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aim<\/jats:title>\n                    <jats:p>Risankizumab is a high\u2010cost biologic treatment for chronic plaque psoriasis, an immune\u2010mediated inflammatory disease presenting with painful red scaly skin lesions. Inter\u2010individual heterogeneity in treatment response may be better addressed with personalised rather than fixed dosing. We sought to develop a pharmacokinetic\/pharmacodynamic (PK\/PD) model to characterise the relationship between risankizumab exposure and treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A sequential population PK\/PD model was developed using real\u2010world data (\n                      <jats:italic>UK Biomarkers of Systemic Treatment Outcomes in Psoriasis<\/jats:italic>\n                      study) comprising serial PK and Psoriasis Area and Severity Index (PASI) measures. Models were built using R (V4.3.1) and nlmixr2 (V2.1.1.9). One and two\u2010compartment PK models were tested. A maximal effect turnover model was used to describe PASI, with drug effect on lesion development rate (\n                      <jats:italic>K<\/jats:italic>\n                      <jats:sub>\n                        <jats:italic>in<\/jats:italic>\n                      <\/jats:sub>\n                      ).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The dataset (82 serum risankizumab concentrations; 101 PASI observations) comprised 50 patients with psoriasis (median weight 79.3\u00a0kg; age 47\u2009years). PK data were described by a one\u2010compartment model with first\u2010order absorption\/elimination. Absorption rate (K\n                      <jats:sub>\n                        <jats:italic>a<\/jats:italic>\n                      <\/jats:sub>\n                      ) was fixed from the literature (0.229). Estimated clearance was 0.34\u2009L\/day, and volume of distribution 12.9\u00a0L. Baseline PASI at model initiation, drug potency (EC\n                      <jats:sub>50<\/jats:sub>\n                      ) and lesion recovery rate (K\n                      <jats:sub>\n                        <jats:italic>out<\/jats:italic>\n                      <\/jats:sub>\n                      ) were estimated at 23.4, 0.11\u2009mg\/L and 0.05\u2009day\n                      <jats:sup>\n                        <jats:italic>\u2212<\/jats:italic>\n                        1\n                      <\/jats:sup>\n                      , respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      Pharmacokinetic parameters were similar to risankizumab clinical trials. K\n                      <jats:sub>\n                        <jats:italic>out<\/jats:italic>\n                      <\/jats:sub>\n                      estimates aligned with other psoriasis turnover models, highlighting the capture of disease dynamics that may be applied across drugs. This model may inform personalised dosing based on individual patient characteristics, drug exposure and response, to optimise treatment outcomes.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70477","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T03:26:05Z","timestamp":1771212365000},"page":"2136-2146","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacokinetic\u2010pharmacodynamic modelling of risankizumab using chronic plaque psoriasis real\u2010world data"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7866-6991","authenticated-orcid":false,"given":"Charlotte M.","family":"Thomas","sequence":"first","affiliation":[{"name":"King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Ruoheng","family":"Wei","sequence":"additional","affiliation":[{"name":"King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Baudry","sequence":"additional","affiliation":[{"name":"King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehra","family":"Arkir","sequence":"additional","affiliation":[{"name":"Clinical Biochemistry, Barts Health  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bola","family":"Coker","sequence":"additional","affiliation":[{"name":"Guy's &amp; St Thomas' Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tejus","family":"Dasandi","sequence":"additional","affiliation":[{"name":"Guy's &amp; St Thomas' Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kingsley","family":"Powell","sequence":"additional","affiliation":[{"name":"King's College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Arenas\u2010Hernandez","sequence":"additional","affiliation":[{"name":"Guy's &amp; St Thomas' Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Leung","sequence":"additional","affiliation":[{"name":"Guy's &amp; St Thomas' Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystal","family":"Rawstron","sequence":"additional","affiliation":[{"name":"Guy's &amp; St Thomas' Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chioma","family":"Nwaogu","sequence":"additional","affiliation":[{"name":"Guy's &amp; St Thomas' Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Woolf","sequence":"additional","affiliation":[{"name":"Guy's &amp; St Thomas' Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew E.","family":"Pink","sequence":"additional","affiliation":[{"name":"King's College London  London UK"},{"name":"Guy's &amp; St Thomas' Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Barker","sequence":"additional","affiliation":[{"name":"King's College London  London UK"},{"name":"Guy's &amp; St Thomas' Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4561-7173","authenticated-orcid":false,"given":"Joseph F.","family":"Standing","sequence":"additional","affiliation":[{"name":"University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine H.","family":"Smith","sequence":"additional","affiliation":[{"name":"King's College London  London UK"},{"name":"Guy's &amp; St Thomas' Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4692-3794","authenticated-orcid":false,"given":"Satveer K.","family":"Mahil","sequence":"additional","affiliation":[{"name":"King's College London  London UK"},{"name":"Guy's &amp; St Thomas' Hospital  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,2,15]]},"reference":[{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590"},{"key":"e_1_2_10_5_1","volume-title":"Psoriasis: assessment and management","author":"for Health NI, Excellence C"},{"key":"e_1_2_10_6_1","volume-title":"Risankizumab for treating moderate to severe plaque psoriasis","author":"for Health NI, Excellence C","year":"2019"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2024.115421"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.03.012"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16101295"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics16121576"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2025.01.031"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2015.1032491"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(18)31713\u20106"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010019\u201000759\u2010z"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19341"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2020.0723"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)30952-3"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13020495"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15378"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19039"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2009.03562.x"},{"key":"e_1_2_10_22_1","volume-title":"Biomarkers of systemic treatment outcomes in psoriasis (BSTOP) protocol","author":"BSTOP","year":"2023"},{"key":"e_1_2_10_23_1","volume-title":"British Association of Dermatologists biologics and immunomodulators registry (BADBIR) website","author":"BADBIR"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012299115260"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.18333"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40744\u2010022\u201000495\u20100"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2831"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.12725"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009343695"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2023.10.022"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.103"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.312"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928\u2010018\u20109581\u20101"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.1594"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12948"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70477","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70477","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70477","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T06:33:40Z","timestamp":1784097220000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70477"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/bcp.70477"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70477","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,15]]}}}